Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well [Seeking Alpha]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Seeking Alpha
INSM is positioned to expand ARIKAYCE's label to 1st-line MAC patients [200k+], convert accelerated to full approval for refractory MAC, and pursue Japanese label expansion. BRINSUPRI is approved for non-cystic fibrosis bronchiectasis, with 2026 revenue guidance of at least $1 billion; ARIKAYCE 2025 sales reached $433.8 million, up 19% YoY. TPIP advances into phase 3 for PAH and PH-ILD, while brensocatib targets immunology and inflammatory indications, supporting a multi-blockbuster pipeline outlook. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Rasi Bhadramani/iStock via Getty Images The last time I spoke about Insmed INSM ) it was with a Seeking Alpha article entitled " Insmed: Company Presses On With Further POC PAH Treatment Data ." With respect to this More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central p
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed (INSM) had its price target raised by Mizuho from $204.00 to $206.00. They now have an "outperform" rating on the stock.MarketBeat
- Insmed (INSM) had its price target raised by Leerink Partners from $210.00 to $215.00. They now have an "outperform" rating on the stock.MarketBeat
- Insmed (INSM) had its price target raised by Stifel Nicolaus from $205.00 to $208.00. They now have a "buy" rating on the stock.MarketBeat
- Insmed eyes Arikayce label expansion on Phase IIIb lung disease success [Yahoo! Finance]Yahoo! Finance
- Insmed (INSM) had its price target raised by Bank of America Corporation from $211.00 to $213.00. They now have a "buy" rating on the stock.MarketBeat
INSM
Earnings
- 2/19/26 - Miss
INSM
Sec Filings
- 3/23/26 - Form 8-K
- 3/20/26 - Form 4
- 3/19/26 - Form 144
- INSM's page on the SEC website